TY - JOUR
T1 - Lichenoid dermatitis from immune checkpoint inhibitor therapy
T2 - An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features
AU - Tetzlaff, Michael T.
AU - Tang, Sherry
AU - Duke, Taylor
AU - Grabell, Daniel A.
AU - Cabanillas, Maria E.
AU - Zuo, Zhuang
AU - Yao, James C.
AU - Nagarajan, Priyadharsini
AU - Aung, Phyu P.
AU - Torres-Cabala, Carlos A.
AU - Duvic, Madeleine
AU - Prieto, Victor G.
AU - Huen, Auris
AU - Curry, Jonathan L.
N1 - Publisher Copyright:
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Cutaneous immune-related adverse events (irAEs) are a known consequence of immune checkpoint inhibitor (ICI) therapy and may exhibit a spectrum of morphologic features both clinically and histologically. Lichenoid dermatitis associated with ICI therapy (LD-ICI) is the most frequently encountered histopathologic type of irAE biopsied by dermatologists. There is frequent clinical and histologic overlap between irAEs and several reactive and neoplastic dermatologic disorders; thus, clinical information is essential. LD-ICI with histologic, immunohistochemical, and molecular features typical of mycosis fungoides (MF) are unique. Here, we report a patient who developed LD-ICI with MF-like morphologic features with monoclonal T-cell receptor gene rearrangement on consecutive biopsies during ICI therapy. The development of monoclonal LD-ICI is important for clinicians and pathologists to recognize in patients receiving ICI therapy.
AB - Cutaneous immune-related adverse events (irAEs) are a known consequence of immune checkpoint inhibitor (ICI) therapy and may exhibit a spectrum of morphologic features both clinically and histologically. Lichenoid dermatitis associated with ICI therapy (LD-ICI) is the most frequently encountered histopathologic type of irAE biopsied by dermatologists. There is frequent clinical and histologic overlap between irAEs and several reactive and neoplastic dermatologic disorders; thus, clinical information is essential. LD-ICI with histologic, immunohistochemical, and molecular features typical of mycosis fungoides (MF) are unique. Here, we report a patient who developed LD-ICI with MF-like morphologic features with monoclonal T-cell receptor gene rearrangement on consecutive biopsies during ICI therapy. The development of monoclonal LD-ICI is important for clinicians and pathologists to recognize in patients receiving ICI therapy.
KW - dermatologic toxicity
KW - immune checkpoint inhibitor
KW - immune-related adverse events
KW - lichenoid dermatitis
KW - mycosis fungoides
UR - http://www.scopus.com/inward/record.url?scp=85069850492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069850492&partnerID=8YFLogxK
U2 - 10.1111/cup.13536
DO - 10.1111/cup.13536
M3 - Article
C2 - 31254410
AN - SCOPUS:85069850492
SN - 0303-6987
VL - 46
SP - 872
EP - 877
JO - Journal of cutaneous pathology
JF - Journal of cutaneous pathology
IS - 11
ER -